Clinical Trial Results:
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis.
Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006;
+ Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005.
Summary
|
|
EudraCT number |
2005-001388-71 |
Trial protocol |
SE AT CZ IT |
Global completion date |
26 Feb 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
08 Dec 2016
|
First version publication date |
08 Dec 2016
|
Other versions |
|
Summary report(s) |
CV185-017_Synopses |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.